Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 86

Sort by

Sort Order Select

Journal Articles

Update on Monocentric CD19-CAR T-Cell Therapy in 30 Patients with Autoimmune Disease

Blood (2024) 144 (Supplement 1): 684.

https://doi.org/10.1182/blood-2024-206163

Published: 2024

Journal Articles

Distinct Safety and Toxicity Profile of CD19-Directed CAR T-Cell Therapy in Systemic Lupus Erythematosus Versus B-Cell Lymphoma - a Single-Center Experience

Blood (2024) 144 (Supplement 1): 4835.

https://doi.org/10.1182/blood-2024-207051

Published: 2024

Journal Articles

Deciphering Inflammasome Activation in Gaucher Macrophages and Its Role in the Development of Multiple Myeloma

Vivien Reinecke, Daniel Hofbauer, Jörg-Thomas Bittenbring, Christopher Lischer, Johannes Berges, Gina Nusser, Katrin Bitterer, Simon Voelkl, Dimitrios Mougiakakos, Andreas Mackensen, Heiko Bruns

Blood (2024) 144 (Supplement 1): 1153.

https://doi.org/10.1182/blood-2024-203108

Published: 2024

Journal Articles

CAR-T Cell Therapy in Patients with Refractory Systemic Autoimmune Diseases Exhibits Less Inflammation, Toxicities and Different Cellular Dynamics Compared to Patients with B Cell Lymphoma

Blood (2023) 142 (Supplement 1): 6871.

https://doi.org/10.1182/blood-2023-188830

Published: 2023

Journal Articles

Prevention of CMV/EBV Reactivation By Double-Specific T Cells in Patients after Allogeneic Stem Cell Transplantation: Results from the Randomized Phase I/IIa Multivir-01 Study

Blood (2023) 142 (Supplement 1): 6849.

https://doi.org/10.1182/blood-2023-178273

Published: 2023

Journal Articles

Impact of Sex on Clinical Outcomes after CD19 CAR T-Cell Therapy for Large B-Cell Lymphoma: Response and Survival Are Significantly Superior in Female Compared to Male Patients

Blood (2023) 142 (Supplement 1): 3787.

https://doi.org/10.1182/blood-2023-186510

Published: 2023

Journal Articles

Immune-Effector-Cell-Associated-Neurotoxicity-Syndrome (ICANS) Pathophysiology Is Mediated By Microglia TGF-β-Activated Kinase-1 Signaling

Janaki Manoja Vinnakota, Francesca Biavasco, Marius Schwabenland, Chintan Chhatbar, Rachael C Adams, Daniel Erny, Sandra Duquesne, Nadia El Khawanky, Henrike Salié, Dimitrios Athanassopoulos, Lukas Braun, Dominik Schmidt, Viktor Fetsch, Rebeka N. Javorniczky, Jenny N.H.G Ho, Reinhard Marks, Ralph Wäsch, Federico Simonetta, Geoffroy Andrieux, Dietmar Pfeifer, Gianni Monaco, Christian Capitini, Terry J. Fry, Thomas Blank, Bruce R Blazar, Eva-Maria Wagner Drouet, Matthias Theobald, Clemens Sommer, Matthias Stelljes, Christian Reicherts, Astrid Jeibmann, Jens Schittenhelm, Camelia-Maria Monoranu, Andreas Rosenwald, K. Martin Kortüm, Leo Rasche, Hermann Einsele, Philipp Tobias Meyer, Joachim Brumberg, Andreas Mackensen, Michael von Bergwelt-Baildon, Roland Coras, Nathalie L. Albert, Laura M. Bartos, Matthias Brendel, Adrien Holzgreve, Melanie Boerries, Crystal L. Mackall, Justus Duyster, Natalie Koehler, Felix Strübing, Bertram Bengsch, Marco Ruella, Marion Subklewe, Louisa von Baumgarten, Saar Gill, Marco Prinz, Robert Zeiser

Blood (2023) 142 (Supplement 1): 100.

https://doi.org/10.1182/blood-2023-184867

Published: 2023

Journal Articles

CD19-Targeted CAR-T Cells in Refractory Systemic Autoimmune Diseases: A Monocentric Experience from the First Fifteen Patients

Blood (2023) 142 (Supplement 1): 220.

https://doi.org/10.1182/blood-2023-180547

Published: 2023

Journal Articles

Block of Counter-Regulation By Inhibition of Protein Synthesis Sensitizes Cancer Cells to IRE1α-Mediated Apoptosis Following Unfolded Protein Response

Franziska Gsottberger, Christina Meier, Anna Ammon, Scott Parker, Kerstin Wendland, Rebekka George, Srdjan Petkovic, Lisa Mellenthin, Charlotte Emmerich, Gloria Lutzny-Geier, Markus Metzler, Andreas Mackensen, Vidyalakshmi Chandramohan, Fabian Mueller

Blood (2022) 140 (Supplement 1): 3122.

https://doi.org/10.1182/blood-2022-169012

Published: 2022

Journal Articles

Sars-Cov-2 Vaccine-Induced Cellular and Humoral Immunity in Patients after CD19.CAR-T Cell Therapy

Hannah Reimann, Anita Natalie Kremer, Viktoria Blumenberg, Katja Schmidt, Michael Aigner, Andreas Kremer, Matthias Tenbusch, Heiko Bruns, Thomas Harrer, Georg Schett, Fabian Mueller, Andreas Mackensen, Marion Subklewe, Simon Voelkl

Blood (2022) 140 (Supplement 1): 10279–10280.

https://doi.org/10.1182/blood-2022-165968

Published: 2022

Journal Articles

CD19-Targeted CAR-T Cells in Refractory Systemic Lupus Erythematosus: Safety, Efficacy, and Mechanistic Insights from the First Five Patients

Fabian Mueller, Simon Voelkl, Dimitrios Mougiakakos, Sebastian Boeltz, Michael Aigner, Regina Gary, Sascha Kretschmann, Soraya Kharboutli, Arnd Kleyer, David Simon, Wolf Rösler, Katharina M. Habenicht, Thomas H. Winkler, Gerhard Krönke, Georg Schett, Andreas Mackensen

Blood (2022) 140 (Supplement 1): 4562–4563.

https://doi.org/10.1182/blood-2022-165077

Published: 2022

Journal Articles

Expansion of Plasmablasts at Day 90 after Allogeneic Stem Cell Transplantation Predict Chronic Gvhd

Katharina M. Habenicht, Anna Bootz, Simon Schäfer, Ingrid Vasova, Matthias Fante, Andrea Schneider, Michael Rehli, Petra Hoffmann, Wolf Roesler, Matthias Edinger, Wolfgang Herr, Andreas Mackensen, Daniel Wolff, Julia Winkler, Thomas H. Winkler

Blood (2022) 140 (Supplement 1): 4776–4777.

https://doi.org/10.1182/blood-2022-165915

Published: 2022

Journal Articles

Inferior Outcomes of EU Vs. US Patients with Relapsed/Refractory Large B-Cell Lymphoma after CD19 CAR T-Cell Therapy Are Associated with Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization and CAR-T Product Selection

Blood (2022) 140 (Supplement 1): 2411–2413.

https://doi.org/10.1182/blood-2022-165452

Published: 2022

Journal Articles

Detection of Signature Double-Negative T Cells Is a Reliable Marker for ALPS Associated with FAS Mutation

Nina Eisenhauer, Maurizio Miano, Nora Naumann-Bartsch, Joerg Leyh, Paola Terranova, Claas Hinze, Michael Aigner, Helmut Wittkowski, Heiko Bruns, Stephan Ehl, Markus Metzler, Peter Arkwright, Andreas Mackensen, Anne Rensing-Ehl, Simon Voelkl

Blood (2022) 140 (Supplement 1): 11194.

https://doi.org/10.1182/blood-2022-168550

Published: 2022

Journal Articles

Alterations of Immune Cells By Large B Cell Lymphoma Persist Years after Achieving Complete Remission and Correlate with Impaired Adaptive Immunity

Richard Pelzl, Sabrina Kübel, Paulina Klein, Franziska Gsottberger, Kerstin Wendland, Srdjan Petkovic, Valeska Brueckl, Rebecca Baur, Simon Voelkl, Andreas Mackensen, Krystelle Nganou-Makamdop, Fabian Müller

Blood (2022) 140 (Supplement 1): 6432–6433.

https://doi.org/10.1182/blood-2022-167216

Published: 2022

Journal Articles

Blocking the CD47-Sirpa Axis Enhances Tafasitamab-Mediated Phagocytosis

Blood (2022) 140 (Supplement 1): 9292–9293.

https://doi.org/10.1182/blood-2022-159955

Published: 2022

Journal Articles

Early Real Time Quantification of CD19. CAR T Cells By Flow Cytometry As a Predictive Biomarker for Response in Patients with R/R LBCL

Blood (2022) 140 (Supplement 1): 7522–7523.

https://doi.org/10.1182/blood-2022-168874

Published: 2022

Journal Articles

Biphasic Neutrophil Recovery after CD19 CART in R/R LBCL Is Associated with Superior PFS/OS, Robust CAR T-Cell Expansion in Relation to Baseline Tumor Volume, and a Decrease of Systemic Inflammation over Time

Blood (2022) 140 (Supplement 1): 4549–4551.

https://doi.org/10.1182/blood-2022-167632

Published: 2022

Journal Articles

CAR-HEMATOTOX: a model for CAR T-cell–related hematologic toxicity in relapsed/refractory large B-cell lymphoma

Blood (2021) 138 (24): 2499–2513.

https://doi.org/10.1182/blood.2020010543

Published: 2021

Includes: Supplemental data

Journal Articles

A Phase I Open Label Dose Escalation Study of MB-CART19.1 in Relapsed and Refractory CD19+ B Cell Malignancies, Interim Preliminary Results in Pediatric ALL, Adult ALL Including CLL Cohorts

Andreas Mackensen, Linda Hanssens, Matthias Stelljes, Wolfgang A Bethge, Tobias Feuchtinger, Annette Künkele, Michael Aigner, Alisa Yakushina, Sandra Karitzky, Silke Holtkamp, Mario Assenmacher, Marion Jurk, Georg Rauser, Dina Schneider, Claudia Rossig

Blood (2021) 138 (Supplement 1): 3836.

https://doi.org/10.1182/blood-2021-152452

Published: 2021

NARROW

Update on Monocentric CD19-CAR T-Cell Therapy in 30 Patients with Autoimmune Disease

Distinct Safety and Toxicity Profile of CD19-Directed CAR T-Cell Therapy in Systemic Lupus Erythematosus Versus B-Cell Lymphoma - a Single-Center Experience

Deciphering Inflammasome Activation in Gaucher Macrophages and Its Role in the Development of Multiple Myeloma

CAR-T Cell Therapy in Patients with Refractory Systemic Autoimmune Diseases Exhibits Less Inflammation, Toxicities and Different Cellular Dynamics Compared to Patients with B Cell Lymphoma

Prevention of CMV/EBV Reactivation By Double-Specific T Cells in Patients after Allogeneic Stem Cell Transplantation: Results from the Randomized Phase I/IIa Multivir-01 Study

Impact of Sex on Clinical Outcomes after CD19 CAR T-Cell Therapy for Large B-Cell Lymphoma: Response and Survival Are Significantly Superior in Female Compared to Male Patients

Immune-Effector-Cell-Associated-Neurotoxicity-Syndrome (ICANS) Pathophysiology Is Mediated By Microglia TGF-β-Activated Kinase-1 Signaling

CD19-Targeted CAR-T Cells in Refractory Systemic Autoimmune Diseases: A Monocentric Experience from the First Fifteen Patients

Block of Counter-Regulation By Inhibition of Protein Synthesis Sensitizes Cancer Cells to IRE1α-Mediated Apoptosis Following Unfolded Protein Response

Sars-Cov-2 Vaccine-Induced Cellular and Humoral Immunity in Patients after CD19.CAR-T Cell Therapy

CD19-Targeted CAR-T Cells in Refractory Systemic Lupus Erythematosus: Safety, Efficacy, and Mechanistic Insights from the First Five Patients

Expansion of Plasmablasts at Day 90 after Allogeneic Stem Cell Transplantation Predict Chronic Gvhd

Inferior Outcomes of EU Vs. US Patients with Relapsed/Refractory Large B-Cell Lymphoma after CD19 CAR T-Cell Therapy Are Associated with Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization and CAR-T Product Selection

Detection of Signature Double-Negative T Cells Is a Reliable Marker for ALPS Associated with FAS Mutation

Alterations of Immune Cells By Large B Cell Lymphoma Persist Years after Achieving Complete Remission and Correlate with Impaired Adaptive Immunity

Blocking the CD47-Sirpa Axis Enhances Tafasitamab-Mediated Phagocytosis

Early Real Time Quantification of CD19. CAR T Cells By Flow Cytometry As a Predictive Biomarker for Response in Patients with R/R LBCL

Biphasic Neutrophil Recovery after CD19 CART in R/R LBCL Is Associated with Superior PFS/OS, Robust CAR T-Cell Expansion in Relation to Baseline Tumor Volume, and a Decrease of Systemic Inflammation over Time

CAR-HEMATOTOX: a model for CAR T-cell–related hematologic toxicity in relapsed/refractory large B-cell lymphoma

A Phase I Open Label Dose Escalation Study of MB-CART19.1 in Relapsed and Refractory CD19+ B Cell Malignancies, Interim Preliminary Results in Pediatric ALL, Adult ALL Including CLL Cohorts

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only